Jump to Main Content

FDA Alerts

FDA Grants Accelerated Approval to Acalabrutinib for Mantle Cell Lymphoma

The Food and Drug Administration granted accelerated approval to acalabrutinib (Calquence™, AstraZeneca Pharmaceuticals Inc. under license of Acerta Pharma BV) for treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.